Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413516 | 1.00 | PRMT5 (0.42) | PRMT5CDK1CDK2MKNK1MKNK2 | |
| SCHEMBL5505830 | 0.89 | PRMT5 (0.38) | PRMT5KDM4EMAPTALDH1A1LMNA | |
| SCHEMBL5264585 | 0.88 | PRMT5 (0.38) | PRMT5KDM4EMAPTALDH1A1GAA | |
| Water SCHEMBL5259730 | 0.87 | PRMT5 (0.37) | PRMT5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL311313 | 0.80 | MMP2 (0.38) | PRMT5KDM4EMAPTALDH1A1BRD4 | |
| SCHEMBL212131 | 0.78 | TLR7 (0.44) | KDM4EMAPTALDH1A1GAAHPGD | |
| SCHEMBL29694218 | 0.78 | TLR7 (0.44) | KDM4EMAPTALDH1A1GAAHPGD | |
| Hydrochloric Acid SCHEMBL5523405 | 0.77 | RAB9A (0.44) | KDM4EMAPTALDH1A1GAAHPGD | |
| SCHEMBL842050 | 0.77 | PRMT5 (0.42) | PRMT5CDK1CDK2MKNK1MKNK2 | |
| SCHEMBL1140927 | 0.75 | DHFR (0.42) | CDK2DHFRBRD4PDPK1GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845980-A2 | AQUEOUS GEL FORMULATIONS CONTAINING 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | claimed |
| EP-1844201-A2 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006084251-A2 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE REPONSE MODIFIERS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| WO-2006084073-A2 | AQUEOUS GEL FORMULATIONS CONTAINING 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-10 | — | — | WO | claimed |
| EP-3889158-B1 | FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3887369-B1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240140946-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-05-02 | — | — | US | disclosed |
| US-11884662-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230406855-A1 | N-1 BRANCHED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-12-21 | — | — | US | disclosed |
| US-20230346954-A1 | N-1 BRANCHED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-11-02 | — | — | US | disclosed |
| EP-3802536-B1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046192-A2 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046191-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046190-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046188-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| US-6194425-B1 | VIRICIDES, ANTITUMOR AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-1040112-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999029693-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406855-A1 | N-1 BRANCHED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | IFNG, NOD1, IL2 | PRMT5 1578/4885CDK1 762/4885CDK2 2482/4885 |
| US-11884662-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, CCL5 | PRMT5 1102/4885CDK1 497/4885CDK2 532/4885 |
| US-20230346954-A1 | N-1 BRANCHED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | IFNG, NOD1, IL2 | PRMT5 1578/4885CDK1 762/4885CDK2 2482/4885 |
| US-20240140946-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, CCL5 | PRMT5 1751/4885CDK1 841/4885CDK2 842/4885 |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, IRF3 | PRMT5 1383/4885CDK1 683/4885CDK2 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.